NCT05017402Not yet recruiting
Higher Dose of Alglucosidase Alpha for Pompe Disease
Higher Dose of Alglucosidase Alpha for Pompe Disease: Long-term Follow-up Study
Source: ClinicalTrials.gov · Last updated 23 Aug 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is aimed to investigate that whether the higher dose ERT improve safety and clinical outcomes of Pompe disease patients. Also, wish to develop a new therapeutic recommendation and hope that it could improve the long-term outcomes of Pompe diesease patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 36 (estimated)
- First submitted
- 5 Aug 2021
- Start date
- 1 Sept 2021
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Taipei Veterans General Hospital, Taiwan
- Diseases
- Pompe disease
- NCT number
- NCT05017402
What you commit to
- Study type: Observational
- Planned participants: 36
- From 1 Sept 2021 to the primary completion date, 31 Dec 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy to Myozyme
Other
- Lost follow-up for clinical visits
- Refuse to sign informed consent
Who the study is looking for
- Diagnosis of Pompe disease
- Currently receiving ERT with regular clinic visits
- Agree to sign informed consent
Age in the registry: 0 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.